Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety, Reactogenicity and Immunogenicity of FluBlok Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly to Healthy Children Aged 6 To 59 Months

NCT00336453 is registered in ClinicalTrials.gov with Protein Sciences Corporation as lead sponsor.

NCT NCT00336453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00336453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety, Reactogenicity and Immunogenicity of FluBlok Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly to Healthy Children Aged 6 To 59 Months
Lead sponsor
Protein Sciences Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2006
Completion date
July 31, 2007
Enrollment
156 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza